Therapy News and Research

RSS

Molecular subtyping determines breast cancer patients at high risk of disease recurrence

A method called molecular subtyping can help doctors better determine which of their breast cancer patients are at high risk of getting breast cancer again, a new study led by the University of South Florida reports.

7 Mar 2014

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development.

7 Mar 2014

Research: Expanded smoking cessation benefits should give more people opportunity to quit

People on Medicaid in the U.S. are 68 percent more likely to smoke than the general population. New research in the American Journal of Preventive Medicine suggests that expanded smoking cessation benefits offered under the Affordable Care Act (ACA) should give more people the opportunity to quit.

7 Mar 2014

Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) today announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.

6 Mar 2014

New findings shed light on how gene mutation causes motor neurone disease

Researchers have discovered a mechanism that may explain how a recently discovered mutation causes two devastating neurological diseases.

6 Mar 2014

Circadian dysfunction blamed for sleepiness in PD patients

Patients with Parkinson’s disease, particularly those with excessive daytime sleepiness, have reduced melatonin levels and amplitude of the melatonin circadian rhythm, research shows.

6 Mar 2014

Researcher wins grant from NCI to continue developing new therapy for bladder cancer

A biomedical engineering researcher at the University of Arkansas will use a $416,897 grant from the National Cancer Institute to continue developing a new therapy for bladder cancer.

6 Mar 2014

Researchers identify high-speed cellular transport mechanism

Our DNA and its architecture are duplicated every time our cells divide. Histone proteins are key building blocks of this architecture and contain crucial information that regulates our genes. Danish researchers show how an enzyme controls reliable and high-speed delivery of histones to DNA copying hubs in our cells. This shuttling mechanism is crucial to maintain normal function of our genes and prevent disease. The results are published in the journal Nature Communications.

6 Mar 2014

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.

6 Mar 2014

Study finds long-term reduction in mortality for young men who undergo radical prostatectomy

More than 230,000 men will be diagnosed with prostate cancer this year in the United States, but determining their course of treatment remains a source of considerable debate. A new study by researchers from Uppsala University Hospital, Sweden, Harvard School of Public Health and colleagues—which draws from one of the few randomized trials conducted to directly address this issue—finds a substantial long-term reduction in mortality for men with localized cancer who undergo a radical prostatectomy.

6 Mar 2014

Important facts about colorectal cancer

Colorectal cancer is the fourth most common cancer in the U.S., with about 143,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years.

6 Mar 2014

Viewpoints: Obama's budget punts on entitlements; Medicaid debate rankles states

There is a lesson in this unexpected juxtaposition nevertheless: No nation can safely base its tax and spending plans on inflexible commitments. Political life, both domestic and international, is too unpredictable. Yet U.S. government spending is mostly on autopilot. The government is scheduled to lay out $3.8 trillion this fiscal year - 70 percent of which will go to mandatory-spending programs, chiefly Social Security, Medicare, Medicaid and interest on the federal debt. Mr. Obama's plan for fiscal 2015 does not change this; it would increase overall spending slightly, paying for it with selected tax increases, while shifting money among priorities here and there. But these tweaks would take place within the same 30 percent of discretionary spending that the current budget contains (3/4).

6 Mar 2014

Scientists reveal how a genetic code variation results in devastating brain diseases

New findings reveal how a mutation, a change in the genetic code that causes neurodegeneration, alters the shape of DNA, making cells more vulnerable to stress and more likely to die.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

Scientists discover fundamental aggravating factor in autoimmune diseases

Scientists in Freiburg may have discovered a fundamental aggravating factor in autoimmune diseases. If B-lymphocytes lack the protein PTP1B, the cells will become hyperactive for stimulatory signals and can thus promote an autoimmune attack.

6 Mar 2014

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Cystic fibrosis is a rare, life-shortening genetic disease for which there is no cure. It affects more than 75,000 people worldwide. In CF, thick, sticky mucus blocks the passages in many organs, leading to a variety of symptoms. In particular, mucus builds up and clogs airways in the lungs making it easier for bacteria to grow.

5 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia®, the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D).

5 Mar 2014

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and DNA Therapeutics, a biopharmaceutical company that is developing a new class of cancer drugs, are renewing their partnership.

5 Mar 2014

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received a new allowance of claims from the U.S. Patent Office, the company’s fourth in the past eight months focused on technology for Parkinson’s disease diagnostics and treatment.

5 Mar 2014

Therapy News and Research

Molecular subtyping determines breast cancer patients at high risk of disease recurrence

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Research: Expanded smoking cessation benefits should give more people opportunity to quit

Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs

New findings shed light on how gene mutation causes motor neurone disease

Circadian dysfunction blamed for sleepiness in PD patients

Researcher wins grant from NCI to continue developing new therapy for bladder cancer

Researchers identify high-speed cellular transport mechanism

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

Study finds long-term reduction in mortality for young men who undergo radical prostatectomy

Important facts about colorectal cancer

Viewpoints: Obama's budget punts on entitlements; Medicaid debate rankles states

Scientists reveal how a genetic code variation results in devastating brain diseases

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Scientists discover fundamental aggravating factor in autoimmune diseases

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News